Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘RBN–2397’

Going beyond PARP1/2 inhibition with novel approaches

Immune cells and tumour cells can act like a changing kaleidoscope depending on the situation

While we have seen many studies on the mechanisms of primary and acquired resistance to small molecule inhibitors leading to rational combination therapies, our understanding of what’s going on under the hood in response to protein degradation or immunotherapies is much less certain.

In our latest post, we explore how these worlds are now starting to collide and how tumour behavior at the time of resistance can better inform translational studies as well as future clinical combinations.

While there have been numerous studies emerging on the dual IO-IO front, let’s not forget there are still many opportunities to explore synergies with small molecule agents to address mechanisms of resistance…

To continue reading our latest discussion on oncology new product development plus expert commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Which early phase agents look promising – or not – ASCO21?

New product development and early phase anti-cancer agents have been very much a focus on BSB (and PSB before it) since their inception.

It’s fascinating to realise one of the compounds selected for review in this article has its origins in a much one earlier trial with serious incidents we saw in a trial in novel volunteers with a different company and product and originally inspired the beginning of our scientific writing in 2006.

By an interesting quirk of history, the first time we wrote about PARP inhibition was in the same year and now it is one of the selections in the ASCO plenary today.  You can read more about the olaparib OlympiaD trial write-up here, proof that all successful products eventually started off in developmental therapeutics at some point in their early career!

In this latest review, we selected eight anti-cancer compounds currently undergoing phase 1/2 trials and put them through their paces… some are more positive than expected, some were downright disappointing, some were off to an encouraging start, others the count is out until we see more robust data.

How is the report card looking this year?  Some reflections and thoughts to consider…

To find out, BSB subscribers can read more on our perspectives regarding Developmental Therapeutics and various early stage compounds, subscribers can log-in or you can click to read our ongoing ASCO21 coverage.

This content is restricted to subscribers

When PARP and immunotherapy worlds collide

Picking a PARPi – what can the biology tell us?

How many observers realised there’s more than one member of the PARP family?

There’s quite a bit to be learned in the DNA damage repair (DDR) and replication stress niche, especially when it’s new targets, new tumour types and even new companies to look at.

In our latest post on this space we switch horses from big Pharma and continue the story with some interesting findings from the biotech side of the R&D fence.

This is a key trend we’ll be following going into ASCO next month as we start to see the layers peeled off the onion and get a lot at what’s working, where it’s working and just as importantly, what’s not…

To learn more about our ongoing post AACR21 and pre ASCO meeting analysis along with a company expert interview to get a heads up on key oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

AACR21 Preview 5 Promising new developments in the PARP field and beyond

Imagine the DDR pathway as a mass of many different notes and targets all interconnected…

We’re on our fifth AACR Preview already this year and there’s plenty more science and clinical topics to cover yet as we go through the emerging topics up on deck.

In this latest update we take a look at the growing field of DNA damage repair – not just old targets, but a raft of emerging ones too, some of which are still in early preclinical development while others are in early phase 1 trials.

We also have some expert commentary on some of these new targets – what stands out, what’s validated and just as importantly, what’s not?

It’s time to get to the centre of things in PARP-land…

To learn more about the hot topics at AACR21 and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

AACR Preview 2 – Pathways to Success in Targeted Therapies

First in class or best in class?

Which paths will ultimately lead to success with novel targeted therapies?

Ah this question often seems a perennial one to consider at AACR annual meetings – and this year is no different in this respect.

Personally, to me, it doesn’t really matter what you claim aspirationally based on preclinical or even early phase 1 dose escalation data because… a lot can happen between then and later registrational studies.

Think about it carefully – weak efficacy, wrong tumour selection or setting, adverse event profiles, even narrow therapeutic windows can all too soon interfere and play havoc like a wrecking ball with many a well intended clinical program, especially once you start looking at combination strategies!

No, it’s not as easy as it looks sometimes.

In our latest AACR Preview series, we take a look at a number of targeted agents in development, many aimed at novel targets at are not run-of-the mill…

To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the annual AACR meeting subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!